Latest by Myles Helfand
Why not all opioid prescriptions are unwise; racial, gender, age, and risk group disparities in HIV care; prophylactic antibiotic use rises among MSM on PrEP; navigating ambiguous HIV test results among PrEP users.
The effect of specific regimens on some birth-related events; obstacles to PrEP among U.S. women; improving mortality and treatment success for HIV-positive people who inject drugs; kidney disease and “old” tenofovir.
Anticholinergics and cognitive performance; gender, physical activity, and cognitive decline; how peer networks can boost HIV self-testing among MSM of color; what HIV care providers don’t know about the Affordable Care Act.
Poor rates of cervical cancer screening for women of color; interest vs. action among potential organ donors; an online depression intervention; Truvada levels in men’s vs. women’s hair.
Alcohol use worsens HIV care outcomes; sex-based differences in cognitive performance seen; higher cardiovascular risk among trans women; glycemic status related to cognitive function.
Early treatment reduces health risks; on-demand PrEP more popular than daily pill among French MSM; long-acting injectable PrEP preferred over daily pill in Swaziland; HIV-positive MSM aren’t testing for syphilis enough.
“Opposites Attract” study piles on more data backing U=U; mixed results on enhanced HIV interventions among African sex workers; the tipping point for re-engagement in HIV care; thyroid function in the modern treatment era.
HIV ramifications of the Trump administration’s anti-immigration efforts; HIV in plasma vs. rectal tissue; how HCV treatment affects HIV/HCV coinfection; HPV vaccination efficacy among women with HIV.
HIV testing disparities among black MSM in the Southern U.S.; reasons for non-adherence in a vaginal HIV prevention ring trial; the importance of PrEP despite successful HIV treatment; inaccurate antiretroviral usage rates in Africa.
Fewer health care visits for PrEP recipients; sexual behavior in the U=U era; HIV and bone issues in women; how Medicaid enrollment gaps affect HIV treatment success.